Human reproduction is dependent upon the actions of follicle-stimulating hormone (hFSH), lutenizing hormone (hLH), and chorionic gonadotropin (hCG). While the a subunits of these heterodimeric proteins can be interchanged without effect on receptor-binding specificity, their (3 subunits differ and direct hormone binding to either LH/CG or FSH receptors. Previous studies employing chemical modifications of the hormones, monoclonal antibodies, or synthetic peptides have implicated hCG (-subunit residues between Cys-38 and Cys-57 and corresponding regions of hLHP and hFSH(3 in receptor recognition and activation. Since the P subunits of hCG or hLH and hFSH exhibit very little sequence similarity in this region, we postulated that these residues might contribute to hormone specificity. To test this hypothesis we constructed chimeric hCG/hFSH ( subunits, coexpressed them with the human a subunit, and examined their ability to interact with LH and FSH receptors and hormone-specific monoclonal antibodies. Surprisingly, substitution of hFSH(3 residues 33-52 for hCG(3 residues 39-58 had no effect on receptor binding or stimulation. However, substitution of hFSH( residues 88-108 in place of the carboxyl terminus of hCG(3 (residues 94-145) resulted in a hormone analog identical to hFSH in Its ability to bind and stimulate FSH receptors. The altered binding specificity displayed by this analog is not attributable solely to the replacement of hCGI3 residues 108-145 or substitution of residues in the "determinant loop" located between hCG(3 residues 93 and 100.
Follicle-stimulating hormone (FSH; follitropin), luteinizing hormone (LH; lutropin), chorionic gonadotropin (CG; choriogonadotropin), and thyroid-stimulating hormone (TSH; thyrotropin) constitute a family of heterodimeric glycoproteins that regulate the development and function of the ovary, testis, and thyroid (1) . Within a species the a subunit is encoded by a single gene and can be interchanged between hormones without effect on receptor binding, whereas the (3 subunits differ and direct binding specificity (2, 3) . Both subunits are required for full biological activity. On the basis of sequence differences between the P subunits and the results of chemical modification studies it has been proposed that amino acid residues between Cys-93 and Cys-100 in human CG ( subunit (hCG() and the corresponding regions of the other hormones form a "determinant loop" which directs hormone specificity (4) . Recent studies have demonstrated that synthetic peptides containing the determinant loop region from hCG(3 (5) or hFSH,8 (6) inhibit the binding of 125I-labeled hormone to receptors, albeit at high concentrations (10-100 EM). The FSH peptide also stimulates granulosa cell steroidogenesis. In addition, phosphorylation of hCG(3 residue Thr-97 disrupts binding to LH receptors (7) .
The region of the ( subunit between Cys-38 and Cys-57 (hCG numbering) has also been proposed to play an important role in receptor binding and stimulation. Synthetic peptides containing hCG, hLH (5), or hFSH (8, 9) ,3-subunit residues from this region inhibit hormone binding and stimulate their respective receptors. In addition, amino acid residues in these regions have been implicated in the recognition of hCG and hFSH by antibodies which inhibit hormone binding to receptors (10) (11) (12) . Proteolytic cleavage of this region of the 83 subunit in ovine LH greatly reduces hormone activity (13) .
We devised a strategy to identify (3-subunit sequences that determine hormone specificity. We postulated that the homologous placement of their 12 cysteine residues ( Fig. 1 Upper) would permit the creation of chimeric hCG/hFSH (3 subunits which would combine with the a subunit. Since hCG and hFSH exhibit low cross-reactivity in receptor binding (17) , we anticipated that we would be able to identify determinants of receptor-binding specificity by comparing the abilities of these heterodimers to bind to LH and FSH receptors. By focusing on a positive endpoint-i.e., switching receptor binding specificity-rather than a negative one such as loss of binding, we expected to be able to distinguish between specific effects of the mutations on binding determinants and nonspecific disruption of hormone structure.
METHODS
Plasmids. Plasmids pSVL-hCG(3 and pSVL-hCGa were constructed by transferring the hCG(3 cDNA from pBR322-chCGj3 (18) or hCGa cDNA from a-hCG/pBR322 (14) into the Sma I site of the transient expression vector pSVL (Pharmacia) using standard techniques (19) . Plasmid pKBM is a derivative of pUC18 (20) ligase (overnight incubation, 15°C), after which the modified plasmid, called pKBM-hCGf3', was isolated from ampicillinresistant colonies of E. coli DH5a. Cassettes encoding the hFSH(3 amino acid sequences illustrated in Fig. 1 Lower were ligated into pKBM-hCGf' between Nae I and Taq I restriction sites (for replacement of hCG,3 amino acid residues 39-58), ApaLl and PpuMI (to replace residues 94-97), or PpuMI and BamHI (to replace residues 108-145). The chimeric constructs were subsequently transferred from pKBM to pSVL, using the unique Xho I and BamHI restriction sites. Plasmid pSVL-3CF94-97 was used to construct CF94-117 and CF94-114 by cassette replacement using the BamHI site and a Sca I site which had been introduced at the codons for residues 97 and 98 (hCG numbering). Constructs containing multiple regions of hFSH,6 in hCG,-i.e., CF39-58+94-97, CF39-58+94-114, and CF39-58+94-117-were assembled by swapping amino acid residues 1-88 from pSVL-,BCF94-97, pSVL-,3CF94-114, or pSVL-13CF94-117 with the corresponding region of pSVL-,8CF39-58, using Pvu II. Cesiumgradient-pure DNA used in transfections was sequenced by using T7 DNA polymerase (22) . Transfection of COS-7 Cells. A previously described DEAE-dextran method (23) was used to cotransfect COS-7 cells (24) with pSVL-derived plasmids containing native or chimeric, subunits and pSVL-hCGa. Eighteen hours after transfection the medium was replaced with serum-free Dulbecco's modifled Eagle's medium (DMEM). After another 72 hr the medium was harvested and centrifuged to remove cellular debris.
Analysis of Biological and Immunological Activity. Monoclonal antibody (mAb) "sandwich assays" used to map or quantify recombinant proteins were performed as described previously (10) . Media harvested from transfected COS-7 cells were concentrated by using Amicon Centriprep-10 concentrators. The recombinant hormones and chimeric analogs were quantified by dimer-specific sandwich assays employing mAbs to human a subunit (A110, A113) and hCG P subunit (B105, B108). Similar results were obtained with either a-or ,B-subunit capture and with different pairs of antibodies. In addition, analogs that bound anti-hFSHB antibody B601 gave comparable results when quantified in an hFSH dimer-specific sandwich assay with mAb B601 and anti-a-subunit mAb E501 (25) .
Membrane-bound LH receptors for the hCG radioligandreceptor assays were obtained from rat corpora lutea induced to superovulate with pregnant mare serum gonadotropin and hCG as described (26) . The FSH radioligand-receptor assays were done with a membrane preparation from bovine testes (8) . Highly purified urinary hCG (CR121) and pituitary hFSH (NIH-AFP-4822-B) were used as reference standards. Labeled hormones (hCG CR121 and NIH-FSH-I-3) were prepared by using an Iodo-Gen-based method (26) .
LH-receptor-mediated steroidogenesis assays were performed as previously described (27) , using a testosterone antiserum obtained from Cambridge Medical Diagnostics. The FSH-receptor-mediated steroidogenesis assays were performed essentially as previously described (28), using granulosa cells obtained from rats implanted with pellets containing diethylstilbestrol (DES). Approximately 40,000-50,000 cells were added to each well of a standard 96-well culture plate to which sterile hormone or analog had already been added to give a final volume of 100 ,ul per well. After 72-hr incubation estradiol was measured directly from aliquots (75 ,ul) of the culture fluid by radioimmunoassay using a highly specific antiserum. At high concentrations (-7.5 x 10-10 M) of hFSH or analogs with FSH activity estradiol production declined. Inhibition did not occur when large incubation volumes (500 ,ul per well of a 24-well plate) were used, suggesting that it was due to the effects of high cell concentration, as noted previously (28) .
RESULTS
Recognition of Chimeric .8 Subunits by mAbs. The structures of the chimeras and the effects of the mutations on 13-subunit conformation were characterized by sandwich assays employing mAbs to hCG and hFSH (Table 1) . Among the antibodies used were A113 (10), which binds the a subunit in both hCG and hFSH, B101 (29) (30) . All of the chimeric 3 subunits combined with a subunit and retained the B105 epitope as indicated by their ability to form sandwiches between B105 and A113 (Table 1) . Chimeras in which hCGB residues 39-58 were replaced with the corresponding region from hFSH(3 (analogs CF39-58, CF39-58+94-97, and CF39-58+94-117) did not bind anti-hCG mAb B101. This finding is consistent with our previous studies, which implicated this region of hCGI3 in B101 binding (10, 11) . These same chimeras were recognized by anti-hFSHB mAb B601 ( Table 1 one production by rat Leydig cells) or hFSH (estradiol production by rat granulosa cells). These assays indicated that the stimulatory activities of the analogs were closely related to their binding activity (Fig. 3) . This suggests that the determinants of receptor binding and activation may be closely linked, or that a region of homologous structure in the different hormones participates in receptor stimulation. Interestingly, while CF94-114, CF94-117, and CF39-58+94-117 were similar to hFSH in their ability to bind and stimulate FSH receptors, they were 10-20 times more potent than hFSH in stimulating Leydig cell steroidogenesis, an "LHspecific" response. Fig. 2 , data for analogs having predominantly hCG activity are illustrated with *, (-, rhCG; -, CF39-58; and . , CF108-114); data for analogs having predominantly hFSH activity are shown with ( 9 rhFSH; --, CF94-117; ---, CF94-114; and * -, CF39-58+94-117); and data for other analogs are shown as A (--, CF94-97 and ---, CF39-58+94-97). The data are depicted as percent maximal testosterone or estradiol synthesis induced by rhCG or rhFSH, respectively, and are a composite from several typical assays (24) . Similar to the results shown for hCG, incubation of granulosa cells with up to 2.5 x 10-9 M CF39-58, CF94-97, CF108-114, or CF39-58+94-97 did not stimulate estradiol production.
tures of glycoprotein hormones their specificity may be determined by a single contiguous region of the subunit.
While we cannot exclude a contribution from the residues corresponding to hCGP 94-97 or 108-114, our data suggest that differences between hCG,8 98-107 and the corresponding region in hFSHP (i.e., 92-101) are particularly important to binding specificity. Within this region hCG and hFSH differ at six residues (hCGP 101-106). All of the chimeric analogs containing hCGP residues 101-106 preferentially bind LH receptors, whereas analogs with the corresponding hFSH residues (i.e., hFSHB 95-100) preferentially bind FSH receptors. The amino acid sequence in this region is completely conserved among the known FSH subunits but is only partly conserved within the LH/CG family, suggesting that it may play a greater role in FSH than in LH/CG function. Interestingly, the ,3 subunit of chicken LH (32) is homologous to hFSH in this region (i.e., Thr-Val-Gln-Gly-Leu-Gly vs.
Thr-Val-Arg-Gly-Leu-Gly). This may explain the preferential binding of chicken LH to mammalian FSH receptors (33) . However, the sequences in this region do not offer as ready an explanation for the ability of equine LH (eLH) or equine CG (eCG) to interact with bovine or rat FSH receptors, since this region of the eLH/eCG p subunit (34) is much more similar to hCGP (i.e., Gly-Val-Phe-Lys-Asp-His vs. Gly-GlyPro-Lys-Asp-His) than to hFSHpS. The observation that the equinep subunit is inactive when combined with a nonequine a subunit (35) suggests that unique features of both equine subunits may contribute to the mixed function seen with eLH and eCG.
Thef/-subunit residues that determine binding specificity may exert their effect through a direct interaction with the target receptor or they might act indirectly by influencing another region of the a or p subunit. Certain antibodies to the a subunit can distinguish between hCG and hFSH, suggesting that the conformation of the a subunit differs between the hormones (36, 37) . Several lines of evidence imply that portions of the region encompassing hCGP residues 94-114 (hFSHp 88-108) may be near the a subunit. Asp-111 in the bovine LH ,8 subunit can be cross-linked to the a subunit (38) , and residues 111-113 of hCG,8 appear to interact with an antibody that binds to determinants on both the a and /8 subunits (39) . In addition, hCGP Thr-97 can be phosphorylated in the free , subunit, but not in the ap heterodimer (40) . An indirect effect of this region on receptor binding through an induced change in hormone structure could explain why peptides in this region of hCG13 and hFSHP8 do not appear to interact with LH or FSH receptors (5, 6) .
The data also reinforce the notion that the various glycoprotein hormone p subunits have highly similar conformations. Even though we chose the least conserved sequences in the proteins for modification and introduced numerous changes in side-chain size, charge, and hydrophobicity, all of the constructs retained binding sites for the a subunit and two or more p-subunit mAbs, and directed binding to LH and/or FSH receptors. Importantly, transfer of hFSHP sequences into hCGP was associated with the development of hFSHspecific activity (antibody or receptor binding), indicating that the transplanted sequences assume conformations similar to those in hFSH. Thus, not only can the intact p subunits be exchanged between hormones to create novel analogs, but portions of their sequences can be exchanged as well.
Since transfer of hFSHO residues 88-108 into hCG,8 results in a hormone analog identical to hFSH in its binding and stimulatory activity, we conclude that these residues and/or conserved features ofhCG and hFSH (in the a subunit and/or ,p subunit) are responsible for activating the receptor. This is consistent with data from previous studies indicating that sequences corresponding to hCG8 residues 93-100 (5) and multiple regions of the a subunit (25) participate in hormonereceptor interactions. However, it is difficult to reconcile our data with models of the hormones which identify the "large loop" regions in the p subunits of hCG (residues 38-57) and hFSH (32-51) as principal binding domains. While high concentrations of synthetic peptides consisting of hCG ,p-subunit residues 38-57 inhibit hCG binding to LH receptors and induce testosterone synthesis (5), the activity of these peptides has been shown to be sensitive to nonconservative amino acid substitutions, particularly substitution for Arg-43 (41) . The activity of the intact hormone appears to be much less sensitive to amino acid substitutions, since the entire 38-57 region of the hCGP subunit can be replaced by residues from hFSH,8 without altering hormone-receptor interactions. This lack of effect is surprising, since 12 of the 16 residues in the loops differ, including substitutions at 7 of the 9 residues which are invariant among the known sequences of mammalian LH and CG p subunits (34) (8, 9) , the "large loop" of hFSH appears to be neither sufficient nor required for full FSH activity of the chimeric subunits. Analogs containing hFSH.3 residues 88-108 are as effective as hFSH,3 in directing binding and stimulation of FSH receptors, regardless of whether they contain other hFSH,3 sequences. Although the hormone receptors appear to be blind to differences in the "large loops," antibodies directed against hCG and hFSH are not, since substitution of the loops is associated with dramatic changes in antibody recognition. This indicates that the two loops do have distinguishing features that can direct specific interactions with other proteins. Perhaps the observed activities of these peptides is unrelated to their conformation in the intact hormone, as has been suggested for the immunological characteristics of certain peptides (42) . Alternatively, conserved structural motifs or residues (Val-44, Gln-54) in the hCG and hFSH P subunits may participate in binding or stimulation of both LH and FSH receptors, despite the overall lack of homology between the two hormones in this region.
In summary, we have shown that hormone-specific characteristics such as receptor or antibody binding specificity can be transferred between glycoprotein hormones as independent "domains" by substitution of contiguous regions in their subunits. In particular we have identified a region of the hFSH p subunit (residues 88-108) that can be used to convert hCG into a follitropin-like protein. When combined with recent progress toward determining the tertiary structures of the glycoprotein hormones (43, 44) and the cloning of their receptors (45, 46) , the ability to build informative mutants and to transfer functional properties between hormones will facilitate our understanding and practical manipulation of their structure.
